Summary
Background
Currently available therapies for advanced pancreatic cancer offer only palliative benefits, and patients with this disease have a poor prognosis. We undertook a phase II trial of ZD1694 (TomudexTM), a quinazoline folate analogue that is a potent and selective thymidylate synthase inhibitor, to determine this analogue's efficacy and safety in patients with advanced pancreatic adenocarcinoma.
Patients and methods
ZD1694, 3.0 mg/m2, was administered to 42 adult patients with pancreatic adenocarcinoma as a 15-minute intravenous infusion every 3 weeks for up to 6 doses. Objective tumor response was assessed every 6 weeks; clinical examinations, adverse event assessments, and clinical laboratory tests were performed every 3 weeks.
Results
ZD1694 produced an overall response rate of 5% (95% confidence limits [CI], 1% to 16%) in the study group. Of 42 patients, 2 (5%) had a partial response, 12 (29%) had stable disease, 21 (50%) had disease progression, and 5 (11%) could not be evaluated for response. Grade 3 vomiting, grades 3 and 4 fever, grade 3 leukopenia, grade 4 thrombocytopenia, and grades 3 and 4 liver function elevations were reported. Toxic effects with ZD1694 were reversible and manageable.
Conclusions
ZD1694 has an acceptable safety profile but limited activity in patients with advanced pancreatic cancer.
Similar content being viewed by others
References
Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CAA Cancer J Clin 45:8–30, 1995
Gudjonsson B: Cancer of the pancreas. Cancer 60:2284–2303, 1987
Cunningham D, Zalcberg, J, Francois Eet al.: Tomudex (ZD1694), a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer (ACC). Proc Annu Meet Am Soc Clin Oncol 13:A584, 1994
Smith IE, Spielmann M, Bonneterre Jet al.: Tomudex (ZD1694), a new thymidylate synthase inhibitor with antitumor activity in breast cancer. Ann Oncol 5 (Suppl 5): 132, 1994
Burris H III, Von Hoff D, Bowen Ket al: A phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Ann Oncol 5 (Suppl 5):133, 1994
Gore M, Earl M, Cassidy Jet al.: Phase II study of Tomudex (ZD1694) in refractory ovarian cancer. Ann Oncol 5 (Suppl 5):133, 1994
Hayward JL, Carbone PP, Henson JCet al.: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89–94, 1977
Author information
Authors and Affiliations
Additional information
Tomudex is a tradename, the property of Zeneca Limited. Supported by a grant from Zeneca Limited.
Rights and permissions
About this article
Cite this article
Pazdur, R., Meropol, N.J., Casper, E.S. et al. Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer. Invest New Drugs 13, 355–358 (1995). https://doi.org/10.1007/BF00873144
Issue Date:
DOI: https://doi.org/10.1007/BF00873144